Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Metastatic castration resistant prostate cancer: Updates from ASCO 2019

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.06.19
Views: 1195
Rating:

Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi

Dr Neal Shore (Carolina Urologic Research Center, South Carolina, USA), Dr Joaquin Mateo (Vall d'Hebron Institute of Oncology, Barcelona, Spain) and Dr Karim Fizazi (Institut Gustave Roussy, Paris, France) discuss the treatment and management of metastatic castration resistant prostate cancer (mCRPC). 

Dr Shore provides and overview of the current treatment landscape for mCRPC before Dr Mateo summarises the TOPARP-A study and results of the TOPARP-B study presented at ASCO 2019. The panel then go on to discuss ongoing trials including PROFOUND and TRITON3 as well as summarising the ARAMIS and VISION studies.

The session concludes with Dr Mateo offering advice on how to manage patients on PARP inhibitors and the associated adverse event profile of this class of drugs.

This programme has been supported by an unrestricted educational grant from AstraZeneca.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation